Media stories about Epizyme (NASDAQ:EPZM) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Epizyme earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.2726385522703 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of equities analysts have recently issued reports on EPZM shares. Cann reaffirmed a “buy” rating and set a $26.00 price target on shares of Epizyme in a research report on Tuesday, December 12th. Royal Bank of Canada lowered shares of Epizyme from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $20.00 to $16.00 in a report on Thursday, November 2nd. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Epizyme in a report on Thursday, November 2nd. ValuEngine lowered shares of Epizyme from a “hold” rating to a “sell” rating in a report on Monday, November 6th. Finally, Leerink Swann reissued an “outperform” rating and set a $22.00 price objective (down from $28.00) on shares of Epizyme in a report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $22.40.
Shares of Epizyme (EPZM) opened at $15.55 on Friday. Epizyme has a 1-year low of $9.30 and a 1-year high of $20.45. The firm has a market cap of $1,080.00, a price-to-earnings ratio of -6.85 and a beta of 2.00.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.02. analysts anticipate that Epizyme will post -2.23 EPS for the current fiscal year.
In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total value of $246,600.00. Following the sale, the insider now directly owns 23,123 shares of the company’s stock, valued at $380,142.12. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 25.20% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Epizyme (EPZM) Stock Price” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/12/epizyme-epzm-earning-somewhat-positive-press-coverage-analysis-shows.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.